Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments

Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments

Bictegravir (BIC) and tenofovir alafenamide fumarate (TAF), two potent anti-HIV drugs, had been nanoformulated (nBIC-TAF) to achieve once-a-month PrEP coverage. In-vivo mouse experiments for nBIC-TAF exhibited favorable subcutaneous (SC) pharmacokinetics. To probe the clinical suitability of the nBI...

Full description

Bibliographic Details
Main Authors: Simone Perazzolo, Subhra Mandal, Pavan K. Prathipati, Christopher J. Destache
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Pharmacology
Subjects:
pre-exposure prophylaxis
HIV
mechanism-based pharmacokinetic modeling
bictegravir
tenofovir alafenamide
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.603242/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.603242/full

Similar Items